Many individuals mistakenly think that the mere presence of symptoms of mental decline are automatic indicators of the presence of Alzheimer’s. This simply is not true.  It takes an experienced doctor to assess the combination of your medical history, biomarkers, and current symptoms to diagnose whether or not you have Alzheimer’s.

According to the Centers for Disease Control[1], more than 5 million Americans are living with Alzheimer’s, most of whom first start experiencing symptoms after age 60 (although more and more individuals are experiencing their first symptoms in their 50s or even late 40s). Right now, the most reliable way to detect Alzheimer’s before it develops or in its earliest stages is with a genetic test to search for the presence of the APOE-4 allele. Again, just because a person has one or more copies of the APOE-4 does not guarantee that they have or will later develop Alzheimer’s—it is simply a risk factor, something like checking your cholesterol as a risk factor for heart disease.

One of Dr. Bredesen’s signature breakthroughs was the development of his ReCODE program to create an accurate way to diagnose the presence of key contributors to Alzheimer’s and risk for Alzheimer’s. Dr. Bredesen also identified and published specific types of Alzheimer’s—in other words, whether the Alzheimer’s is predominantly inflammatory or toxic or due to loss of hormone or nutrient support, etc., which aids in the optimization of a prevention or reversal program. The ReCODE program looks for 36 separate biomarkers to identify whether the APP (amyloid precursor protein) is being programmed to split into the four known destructive components (peptides) or whether it is still converting normally into two healthy chemical components.


  • Increased sense of anxiety.
  • Mood or personality changes, including depression.
  • Increased incidents of aggression.
  • Getting lost in familiar surroundings.
  • Misplacing or losing items in unusual places.
  • A slowdown in how long it takes to perform normal, daily tasks.
  • Memory loss, particularly short-term memory loss.
  • A decline in the ability to exhibit good judgement.
  • Difficulty with numbers or handling money.
  • An increase in rigid mental behavior and loss of spontaneity.
  • Fear and anxiety concerning new experiences or ideas.
  • Difficulty recognizing friends and family members.
  • A sense of restlessness either physical or mental.
  • Difficulty in reading.
  • Trouble completing multi-step tasks like getting dressed.
  • Occasional muscle twitches.
  • Impulsive and inappropriate behavior such as cursing.

According to the National Institutes of Health[2], you should immediately consult a doctor if you are experiencing any of the following symptoms of Alzheimer’s. Your doctor will work with you to better understand your symptoms and decide the best course of treatment for your condition.

Dr. Bredesen’s ReCODE program has analyzed scientific studies across a large population of individuals to properly weigh the significance of and role of the 36 different biomarkers that indicate the malignant APP programming that is believed to be the principal cause of Alzheimer’s.

In a healthy brain, most of the APP protein will be chemically programmed to split into two different molecules that have been shown to protect and promote mental health by supporting the formation of and maintaining the neurites (brain cells) that handle memory.


(APP) is expressed in the synapses of neurons and is thought to be responsible for forming and repairing synapses.

But when there is a malfunction in the APP switching mechanism (for example, due to chronic inflammation), the APP proteins split into four different toxic peptides that then lead to the build-up of amyloid plaques, the shrinkage of the brain, damage to brain cells, and other deteriorations that lead to the visible symptoms of Alzheimer’s like loss of short term memory, depression, and a steady decline in cognitive function.

The ReCODE program measures exactly how and where the APP proteins are being divided into the four known harmful peptides, allowing doctors to pinpoint both the presence and progression of Alzheimer’s disease in an individual.